(March 21, 2016, 1:55 PM EDT) -- WASHINGTON, D.C. — A New Jersey federal judge did not err in holding that two patents relating to oral dosage forms of risedronate and disodium ethylenediaminetetraacetic acid (EDTA) are invalid as obvious, the Federal Circuit U.S. Court of Appeals affirmed March 18 (Warner Chilcott Company LLC, et al. v. Teva Pharmaceuticals USA Inc., No. 15-1588, Fed. Cir.; 2016 U.S. App. LEXIS 4945)....